Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention.

Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M.

N Engl J Med. 2006 Sep 14;355(11):1105-13.

2.

Sirolimus-eluting versus uncoated stents in acute myocardial infarction.

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C; TYPHOON Investigators.

N Engl J Med. 2006 Sep 14;355(11):1093-104.

3.

Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.

Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2009 May 7;360(19):1946-59. doi: 10.1056/NEJMoa0810116.

4.

Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.

Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B.

N Engl J Med. 2005 Aug 18;353(7):653-62. Epub 2005 Aug 16.

5.

Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators.

N Engl J Med. 2010 May 6;362(18):1663-74. doi: 10.1056/NEJMoa0910496.

7.

Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.

Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A; ISAR-DIABETES Study Investigators.

N Engl J Med. 2005 Aug 18;353(7):663-70. Epub 2005 Aug 16.

8.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB.

N Engl J Med. 2007 Mar 8;356(10):998-1008. Epub 2007 Feb 12.

9.

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators.

N Engl J Med. 2004 Jan 15;350(3):221-31.

10.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators.

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

11.

Paclitaxel-eluting versus bare-metal stents in acute ST elevation myocardial infarction (STEMI).

Hamirani YS, Jibrin I, Abraham D, Merriman B, Wenz C, Bahr RD.

Crit Pathw Cardiol. 2008 Dec;7(4):232-8. doi: 10.1097/HPC.0b013e3181805e0b.

PMID:
19050419
12.

Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.

Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ; ZEST-AMI Investigators.

Am J Cardiol. 2009 Nov 15;104(10):1370-6. doi: 10.1016/j.amjcard.2009.06.059. Epub 2009 Sep 26.

PMID:
19892052
13.
14.
15.
16.

Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction.

Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietilä M, Sia J, Tuomainen P, Nyman K, Airaksinen KE.

Ann Med. 2009;41(8):599-607. doi: 10.1080/07853890903111018.

PMID:
19701826
17.

Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction.

Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Bøttcher M, Lassen JF, Hansen KN, Krusell LR, Rasmussen K, Pedersen KE, Pedersen L, Paaske Johnsen S, Sørensen HT, Thuesen L.

Circ Cardiovasc Interv. 2008 Dec;1(3):176-84. doi: 10.1161/CIRCINTERVENTIONS.108.794578.

18.

Very late thrombosis in acute myocardial infarction: drug-eluting versus uncoated stents.

Garro N, Capodanno D, Cammalleri V, Tamburino C.

EuroIntervention. 2008 Nov;4(3):324-30.

PMID:
19110805
19.

Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.

Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME; TAXUS VI Investigators.

Circulation. 2005 Nov 22;112(21):3306-13. Epub 2005 Nov 14.

20.

Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.

Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Stone GW.

J Am Coll Cardiol. 2005 Apr 19;45(8):1165-71.

Supplemental Content

Support Center